Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24, the annual meeting of the American College of Cardiology (ACC), kicked off on Saturday, April 6, with a series of late-breaking clinical trials focused on testing the safety and effectiveness of new treatment strategies.

Day 1 at ACC.24: Late-breakers examine potential new heart attack, heart failure treatments

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies. 

Eko Health, the California-based healthcare technology company known for its advanced stethoscopes, has received U.S. Food and Drug Administration (FDA) approval for a new artificial intelligence (AI) offering designed to detect low ejection fraction (EF).

FDA approves new AI model for detecting signs of heart failure with a stethoscope

Eko Health worked closely with Mayo Clinic to develop and evaluate its latest AI offering. “Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations," one clinician said. 

Newsweek ranked the 50 best heart hospitals in the world

Moderate prosthesis-patient mismatch after SAVR linked to worse long-term outcomes

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.

doctor examines patient data on their tablet

Donor hearts more likely to be accepted when the transplant candidate is female or white

"This finding suggests racial and gender bias as a potential contributor to the organ acceptance decision-making process," researchers wrote in JAMA.

FDA approves new drugs for pulmonary arterial hypertension from Johnson & Johnson, Merck

Cardiologists now have two more tools to help them combat PAH, a rare vascular condition that often leads to heart failure.

healthcare value value-based care money dollar

Novo Nordisk to acquire biotech company working on new heart failure drug for $1.1B

Cardior Pharmaceuticals in Germany has been developing a new compound it says can “halt and partially reverse cellular pathology” in heart failure patients. 

Cardiologist heart

A possible remedy for cardiology’s staffing shortages: heart failure internists

Internal medicine physicians spend a lot of time working with heart failure patients. A new commentary in JACC: Heart Failure explored the potential impact of providing IM trainees with special training so that they can deliver additional value.

Displaying 73 - 80 of 672
Design by Adaptive Theme